Cardiovascular effects of fluoxetine in depressed patients with heart disease

American Journal of Psychiatry

Volumn 155, Issue 5, 1998, Pages 660-665

  Roose, Steven P ^a   Glassman, Alexander H ^b   Attia, Evelyn ^b   Woodring, Sally ^b   Giardina, Elsa Grace V ^b   Bigger Jr , J Thomas ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTERITIS; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0031957125     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.5.660     Document Type: Article

References (24)

1. Williams RB Jr, Sherter C: Cardiac complications of tricyclic antidepressant therapy. Ann Intern Med 1971; 74:395-398
2. Roose SP, Glassman AH: Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J Clin Psychiatry 1989; 50(July suppl):1-18
3. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412
4. Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233
5. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82:1106-1116
6. Morganroth J, Coin JE: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation 1991; 84:1977-1983
7. Bigger JT Jr: Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. Am J Cardiol 1990; 65:3D-10D
8. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788
9. Greenberg HM, Dwyer EM Jr, Hochman JS, Steinberg JS, Echt DS, Peters RW: Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995; 74:631-635
10. Glassman AH, Roose SP, Bigger JT Jr: The safety of tricyclic antidepressants in cardiac patients: risk/benefit reconsidered. JAMA 1993; 269:2673-2675
11. Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270:1819-1825
12. Cooper GL: The safety of fluoxetine - an update. Br J Psychiatry 1988; 153(supp1 3):77-86
13. Kuhs H, Rudolf GAE: Cardiovascular effects of paroxetine. Psychopharmacology (Berl) 1990; 102:379-382
14. Fisch C: Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985; 46(3, part 2):42-44
15. Cardiac Arrhythmia Pilot Study (CAPS) Investigators: The Cardiac Arrhythmia Pilot Study. Am J Cardiol 1986; 57:91-95
16. Roose SP, Glassman AH, Giardina EGV, Johnson LL, Walsh BT, Woodring S, Bigger JT Jr: Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986; 256:3253-3257
17. Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB: Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference. J Clin Psychopharmacol 1981; 1:316-319
18. Classman AH, Johnson LL, Giardina EGV, Walsh BT, Roose SP, Cooper TB, Bigger JT Jr: The use of imipramine in depressed patients with congestive heart failure. JAMA 1983; 250:1997-2001
19. Roose SP, Glassman AH, Giardina EGV, Johnson LL, Walsh BT, Bigger JT Jr: Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987; 7:247-251
20. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV: Is doxepin a safer tricyclic for the heart? J Clin Psychiatry 1991; 52:338-341
21. Dalack GW, Roose SP, Glassman AH: Tricyclics and heart failure (letter). Am J Psychiatry 1991; 148:1601
22. Wernicke JF: The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46(3, part 2):59-67
23. Upward JW, Edwards JG, Goldie A, Waller DC: Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol 1988; 26:399-402
24. Roose SP, Glassman AH, Attia E, Woodring S: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151:1735-1739